BioVex

BioVex was a biotechnology company that developed potent biologics for treating cancer and preventing infectious diseases. The company was founded in 1999 by Robert Coffin as a spin-out from his research group at University College London. Coffin, who holds a PhD in virology from Imperial College London, served as the company's Chief Technology Officer. Initially named NeuroVex and focused on gene therapies for neurological diseases, the company soon shifted its focus to oncology, rebranding as BioVex.

The company's core business revolved around the development of oncolytic vaccines, a class of viruses engineered to selectively replicate in and destroy cancer cells while stimulating the patient's immune system to attack the tumor. The lead product, OncoVEX(GM-CSF), was a modified herpes simplex virus designed to treat solid tumors like melanoma and head and neck cancer. This product works by lysing cancer cells and releasing a substance called GM-CSF, which helps activate a systemic anti-tumor immune response. BioVex also developed a vaccine candidate, ImmunoVEX(HSV2), for the prevention and treatment of genital herpes.

On January 24, 2011, Amgen announced its agreement to acquire BioVex, a deal that was completed on March 4, 2011. The acquisition was valued at up to $1 billion, consisting of $425 million in cash upfront and up to $575 million in milestone payments. At the time of the acquisition, BioVex's lead product, OncoVEX(GM-CSF), was in late-stage Phase 3 clinical trials. Following the acquisition, the product was renamed Talimogene laherparepvec (T-VEC) and later approved by the FDA in October 2015 as IMLYGIC®, becoming the first oncolytic immunotherapy approved in the United States.

Keywords: oncolytic virus therapy, biologics, cancer treatment, infectious disease prevention, melanoma, head and neck cancer, herpes simplex virus, gene therapy, OncoVEX, immunotherapy, Talimogene laherparepvec, T-VEC, IMLYGIC, Amgen acquisition, Robert Coffin, clinical trials, solid tumors, genital herpes vaccine